A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial-Reference-Cited by-同舟云学术

A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial

Published:2009-03-06 Issue:5 Volume:64 Page:1021-1027
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Pisano Carmela,Morabito Alessandro,Sorio Roberto,Breda Enrico,Lauria Rossella,Gebbia Vittorio,Scaltriti Laura,Scalone Simona,Zagonel Vittorina,Greggi Stefano,Beneduce Gerardo,Losito Simona,Gallo Ciro,Di Maio Massimo,Forestieri Valeria,Pignata Sandro

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-009-0958-0.pdf

Reference24 articles.

1. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CAM, Hirsch FR, Lund B, van Houweligen HC (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084–3092

2. du Bois A, Luck H-J, Meier W, Adams H-P, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jaskisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, for the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1330

3. du Bois A, Quinn M, Thigpen T et al, Gynecologic Cancer Intergroup, AGO-OVAR, ANZGOG, EORTC, GEICO, GINECO, GOG, JGOG, MRC/NCRI, NCIC-CTG, NCI-US, NSGO, RTOG, SGCTG, IGCS, Organizational Team of the two prior International OCCC (2005) 2004 Consensus statements on the management of ovarian cancer: final document of the third international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7–viii12

4. Markman M, Reichman B, Hakes T et al (1991) Responses to second-line cisplatin based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801–1805

5. Herzog TJ (2004) Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 10:7439–7449

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis;Pharmaceuticals;2023-03-30

2. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth;Vitamins and Hormones;2018

3. Mucinous ovarian cancer: A therapeutic review;Critical Reviews in Oncology/Hematology;2016-06

4. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study;International Journal of Gynecologic Cancer;2015-07

5. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase;Gynecologic Oncology;2013-08